Cargando…

Oncolytic virus therapy benefits from control theory

Oncolytic virus therapy aims to eradicate tumours using viruses which only infect and destroy targeted tumour cells. It is urgent to improve understanding and outcomes of this promising cancer treatment because oncolytic virus therapy could provide sensible solutions for many patients with cancer. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Anelone, Anet J. N., Villa-Tamayo, María F., Rivadeneira, Pablo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428268/
https://www.ncbi.nlm.nih.gov/pubmed/32874642
http://dx.doi.org/10.1098/rsos.200473
_version_ 1783571037942710272
author Anelone, Anet J. N.
Villa-Tamayo, María F.
Rivadeneira, Pablo S.
author_facet Anelone, Anet J. N.
Villa-Tamayo, María F.
Rivadeneira, Pablo S.
author_sort Anelone, Anet J. N.
collection PubMed
description Oncolytic virus therapy aims to eradicate tumours using viruses which only infect and destroy targeted tumour cells. It is urgent to improve understanding and outcomes of this promising cancer treatment because oncolytic virus therapy could provide sensible solutions for many patients with cancer. Recently, mathematical modelling of oncolytic virus therapy was used to study different treatment protocols for treating breast cancer cells with genetically engineered adenoviruses. Indeed, it is currently challenging to elucidate the number, the schedule, and the dosage of viral injections to achieve tumour regression at a desired level and within a desired time frame. Here, we apply control theory to this model to advance the analysis of oncolytic virus therapy. The control analysis of the model suggests that at least three viral injections are required to control and reduce the tumour from any initial size to a therapeutic target. In addition, we present an impulsive control strategy with an integral action and a state feedback control which achieves tumour regression for different schedule of injections. When oncolytic virus therapy is evaluated in silico using this feedback control of the tumour, the controller automatically tunes the dose of viral injections to improve tumour regression and to provide some robustness to uncertainty in biological rates. Feedback control shows the potential to deliver efficient and personalized dose of viral injections to achieve tumour regression better than the ones obtained by former protocols. The control strategy has been evaluated in silico with parameters that represent five nude mice from a previous experimental work. Together, our findings suggest theoretical and practical benefits by applying control theory to oncolytic virus therapy.
format Online
Article
Text
id pubmed-7428268
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society
record_format MEDLINE/PubMed
spelling pubmed-74282682020-08-31 Oncolytic virus therapy benefits from control theory Anelone, Anet J. N. Villa-Tamayo, María F. Rivadeneira, Pablo S. R Soc Open Sci Engineering Oncolytic virus therapy aims to eradicate tumours using viruses which only infect and destroy targeted tumour cells. It is urgent to improve understanding and outcomes of this promising cancer treatment because oncolytic virus therapy could provide sensible solutions for many patients with cancer. Recently, mathematical modelling of oncolytic virus therapy was used to study different treatment protocols for treating breast cancer cells with genetically engineered adenoviruses. Indeed, it is currently challenging to elucidate the number, the schedule, and the dosage of viral injections to achieve tumour regression at a desired level and within a desired time frame. Here, we apply control theory to this model to advance the analysis of oncolytic virus therapy. The control analysis of the model suggests that at least three viral injections are required to control and reduce the tumour from any initial size to a therapeutic target. In addition, we present an impulsive control strategy with an integral action and a state feedback control which achieves tumour regression for different schedule of injections. When oncolytic virus therapy is evaluated in silico using this feedback control of the tumour, the controller automatically tunes the dose of viral injections to improve tumour regression and to provide some robustness to uncertainty in biological rates. Feedback control shows the potential to deliver efficient and personalized dose of viral injections to achieve tumour regression better than the ones obtained by former protocols. The control strategy has been evaluated in silico with parameters that represent five nude mice from a previous experimental work. Together, our findings suggest theoretical and practical benefits by applying control theory to oncolytic virus therapy. The Royal Society 2020-07-01 /pmc/articles/PMC7428268/ /pubmed/32874642 http://dx.doi.org/10.1098/rsos.200473 Text en © 2020 The Authors. http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.
spellingShingle Engineering
Anelone, Anet J. N.
Villa-Tamayo, María F.
Rivadeneira, Pablo S.
Oncolytic virus therapy benefits from control theory
title Oncolytic virus therapy benefits from control theory
title_full Oncolytic virus therapy benefits from control theory
title_fullStr Oncolytic virus therapy benefits from control theory
title_full_unstemmed Oncolytic virus therapy benefits from control theory
title_short Oncolytic virus therapy benefits from control theory
title_sort oncolytic virus therapy benefits from control theory
topic Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428268/
https://www.ncbi.nlm.nih.gov/pubmed/32874642
http://dx.doi.org/10.1098/rsos.200473
work_keys_str_mv AT aneloneanetjn oncolyticvirustherapybenefitsfromcontroltheory
AT villatamayomariaf oncolyticvirustherapybenefitsfromcontroltheory
AT rivadeneirapablos oncolyticvirustherapybenefitsfromcontroltheory